STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 115796

TO: Rei-Tsang Shiao **Location: 5a10 / 5c18** **Wednesday, March 10, 2004** **Art Unit: 1626** **Phone: 272-0707** **Serial Number: 09 / 766547**	**From: Jan Delaval** **Location: Biotech-Chem Library** **Rem 1A51** **Phone: 272-2504** **jan.delaval@uspto.gov**

Search Notes

-80 ".

Scientific and Technical Information Center

Requester's Full Name: Robert (Rusty) Shiao Examiner #: 79524 Date: 3/1/04

Art Unit: 1626 Phone Number 2-0707 Serial Number: 09/766547

Mail Box and Bldg/Room Location: 5A10 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Thiazole, Imidazol and Oxazole -

Inventors (please provide full names): Wigle et al

Earliest Priority Filing Date:

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

I. search the Methods of use of cpd I or IA



I.

Ra, Rb, Rc are sub

J is O, S.

Rc is O, alkyl.. , Ar,

NHC(=O)-(CH2)n-D-ReR +

Re is formula II

or



IA

II search methods of use of the compounds of claim 6 for treating diabet, kidney damage, hypertension, ...

STAFF USE ONLY

Searcher:		Type of Search		Vendors and cost where applicable	
Searcher Phone #: 22504		NA Sequence (#)		STN	✓
Searcher Location:		AA Sequence (#)		Dialog	
Date Searcher Picked Up: 3/10		Structure (#)	✓	Questel/Orbit	
Date Completed: 3/10		Bibliographic		Dr. Link	
Searcher Prep & Review Time:		Litigation		Lexis/Nexis	
		Fulltext		Sequence Systems	

```
=> d his

     (FILE 'HOME' ENTERED AT 13:37:31 ON 10 MAR 2004)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 13:38:00 ON 10 MAR 2004
L1             1 S US20020022622/PN
               E WAGLE D/AU
L2           181 S E3-E7,E10-E12
               E VASAN S/AU
L3            43 S E3-E9
               E EGAN J/AU
L4           106 S E3,E11,E12
               E EGAN JOHN/AU
L5            66 S E3,E9-E11
               E ALTEON/PA,CS
L6            63 S E3-E10
L7            35 S L2-L5 AND L6
L8            17 S L7 AND HETER?/SC,SX
L9             1 S L1 AND L8
L10           16 S L8 NOT L9
               SEL RN L9

     FILE 'REGISTRY' ENTERED AT 13:40:22 ON 10 MAR 2004
L11           11 S E1-E11
L12           10 S L11 AND NR>=1
L13            2 S L12 AND (C19H14N2O2S OR C13H14N2O2S)

     FILE 'HCAPLUS' ENTERED AT 13:43:54 ON 10 MAR 2004
               SET SMARTSELECT ON
L14          SEL L10 1- RN :     447 TERMS
               SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 13:43:55 ON 10 MAR 2004
L15          447 S L14
L16          158 S L15 AND NCSC2/ES
L17           34 S L16 AND 1/NR
L18            1 S L17 AND CL/ELS
L19           33 S L17 NOT L18
L20           10 S L19 NOT IUM
L21            3 S L20 AND (C7H11NS OR C6H9NS OR C3H3NS)
L22           89 S L16 AND C6/ES
L23           10 S L22 NOT IUM
L24            1 S L23 AND F/ELS
L25          650 S NCSC2/ES AND 46.150.18/RID AND 2/NR AND 2/N AND 1/F AND 1/S A
L26          162 S L25 NOT O/ELS
L27           17 S L26 AND 9/C
L28           15 S L27 AND 4
L29            8 S L28 AND 4 FLUOROPHENYL
L30            5 S L29 NOT CL/ELS
               SEL RN 1 5
L31            2 S E12-E13
L32       160825 S NCSC2-C6/ES
L33         2063 S L32 AND 2/NR AND 1/CL AND 1/NC
L34          862 S L33 AND 2/N
L35          196 S L34 NOT O/ELS
L36          114 S L35 AND 1/S
L37          102 S L36 NOT F/ELS
L38           21 S L37 AND 7/C
L39            5 S L38 AND 4 CHLORO
L40            2 S L39 AND 2
L41            1 S L40 NOT BR/ELS
L42         3991 S L32 AND C6-C6/ES
```

```
L43          388 S L42 AND DIMETHYL
L44           26 S L43 AND ONE
L45           18 S L44 AND 4/NR
L46            8 S L45 AND 2/N
L47            6 S L46 AND 1/NC
L48            5 S L47 AND 1/O
L49            2 S L48 AND 19/C
L50            1 S 109317-64-8
L51            0 S L43 AND TRIHYDRO
L52            4 S L42 AND TRIHYDRO
L53         1269 S L42 AND 4/NR
L54          107 S L53 AND L43
L55           52 S L54 AND 2/N
L56           47 S L55 NOT L48
L57           30 S L56 NOT IUM
L58            9 S L13,L21,L41,L31,L50
L59            3 S L30 NOT L31
L60           12 S L58,L59
                SEL RN
L61           68 S E14-E25/CRN
L62           19 S L61 NOT (MXS/CI OR COMPD OR WITH)
L63           17 S L62 NOT PMS/CI
L64           16 S L63 NOT CONJUGATE

     FILE 'HCAPLUS' ENTERED AT 14:36:18 ON 10 MAR 2004
L65         2744 S L60 OR L64
L66            5 S L1-L6 AND L65
L67            5 S L1,L66
                E AGING/CT
L68        38222 S E3
L69        24980 S E19-E24
                E E19+ALL
L70        33749 S E4,E5
L71        36458 S E3+NT
                E E25+ALL
L72         4936 S E1
                E E6+ALL
L73        67222 S E4,E3+NT
L74            5 S L65 AND L68-L73
                SEL DN AN 1 3 5
L75            3 S E1-E9
L76            6 S L67,L75 AND L1-L10,L65-L75
L77           44 S (L60 OR L64)(L)THU/RL
L78          109 S (L60 OR L64)(L)(ADV OR BAC OR DMA OR PAC OR PKT)/RL
L79          398 S L65 AND (PHARMACEUT? OR PHARMACOL? OR PATHOL?)/SC,SX
L80          473 S L77-L79
L81            5 S L80 AND (AGING OR AGEING)
L82            4 S L81 NOT 30/SC
L83            6 S L76,L82

     FILE 'REGISTRY' ENTERED AT 14:44:11 ON 10 MAR 2004

     FILE 'HCAPLUS' ENTERED AT 14:45:32 ON 10 MAR 2004

     FILE 'REGISTRY' ENTERED AT 14:45:37 ON 10 MAR 2004
                SEL RN L60 7 8 9 12
L84            8 S L60 NOT E10-E13

     FILE 'HCAPLUS' ENTERED AT 14:46:38 ON 10 MAR 2004
L85           34 S L84
L86           18 S L85 AND L80
L87           13 S L86 NOT ?FUNG?
L88           10 S L87 NOT L83
```

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 14:48:17 ON 10 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     9 MAR 2004  HIGHEST RN 660815-69-0
DICTIONARY FILE UPDATES:    9 MAR 2004  HIGHEST RN 660815-69-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d ide can tot l60

L60  ANSWER 1 OF 12  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   441285-73-0  REGISTRY
CN   2-Thiazolidinamine, N-(4-fluorophenyl)- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C9 H11 F N2 S
SR   CA
LC   STN Files:   CA, CAPLUS
```



Gom claim 6
page 50

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE   1:  137:93744

L60  ANSWER 2 OF 12  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   302559-76-8  REGISTRY
CN   Acetamide, 2-(3,5-dimethylphenoxy)-N-2-thiazolyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide
FS   3D CONCORD
MF   C13 H14 N2 O2 S
SR   Chemical Library
LC   STN Files:   CA, CAPLUS, CHEMCATS, USPAT2, USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:93744

REFERENCE 2: 137:93743

REFERENCE 3: 135:122497

L60 ANSWER 3 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN **289491-05-0** REGISTRY
CN 2-Furancarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C19 H14 N2 O2 S**
SR Chemical Library
LC STN Files: CA, CAPLUS, CHEMCATS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:93744

REFERENCE 2: 137:93743

REFERENCE 3: 135:122497

L60 ANSWER 4 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 137935-26-3 REGISTRY
CN **4-Thiazolamine, N-(4-fluorophenyl)-4,5-dihydro- (9CI)** (CA INDEX NAME)
FS 3D CONCORD
MF **C9 H9 F N2 S**
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:6459

L60 ANSWER 5 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN **109317-64-8** REGISTRY
CN 7(4H)-Benzothiazolone, 5,6-dihydro-5,5-dimethyl-2-(2-naphthalenylamino)-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H18 N2 O S
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:93744

REFERENCE 2: 107:58918

L60 ANSWER 6 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 77815-14-6 REGISTRY
CN **2-Thiazolamine, 4-(4-fluorophenyl)- (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **2-Amino-4-(4-fluorophenyl)thiazole**
FS 3D CONCORD
MF **C9 H7 F N2 S**
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
22 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:149652

REFERENCE 2: 137:310439

REFERENCE 3: 133:252829

REFERENCE 4: 131:322593

REFERENCE 5: 131:139512

REFERENCE 6: 128:312900

REFERENCE 7: 127:5225

REFERENCE 8: 126:89392

REFERENCE 9: 122:105732

REFERENCE 10: 118:38821

L60 ANSWER 7 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 19952-47-7 REGISTRY
CN **2-Benzothiazolamine, 4-chloro- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzothiazole, 2-amino-4-chloro- (6CI, 8CI)**
OTHER NAMES:
CN **2-Amino-4-chlorobenzothiazole**
CN **4-Chloro-1,3-benzothiazol-2-ylamine**
CN **4-Chloro-2-benzothiazolamine**
FS 3D CONCORD
MF **C7 H5 Cl N2 S**
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, HODOC*, IFICDB, IFIPAT, IFIUDB, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

146 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
146 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 140:111335

REFERENCE 2: 139:395854

REFERENCE 3: 139:133557

REFERENCE 4: 139:48450

REFERENCE 5: 139:32012

REFERENCE 6: 138:368620

REFERENCE 7: 138:99909

REFERENCE 8: 137:118555

REFERENCE 9: 137:93763

REFERENCE 10: 137:93744

L60 ANSWER 8 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN **18640-74-9** REGISTRY
CN Thiazole, 2-(2-methylpropyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thiazole, 2-isobutyl- (8CI)
OTHER NAMES:
CN 2-(2-Methylpropyl)thiazole
CN 2-Isobutyl-1,3-thiazole
CN 2-Isobutylthiazole
CN NSC 290430
FS 3D CONCORD
MF **C7 H11 N S**
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

112 REFERENCES IN FILE CA (1907 TO DATE)
112 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:162588

REFERENCE 2: 140:127361

REFERENCE 3: 140:24222

REFERENCE 4: 139:364960

REFERENCE 5: 139:363842

REFERENCE 6: 139:349826

REFERENCE 7: 139:261206

REFERENCE 8: 139:229658

REFERENCE 9: 139:229546

REFERENCE 10: 139:51951

L60 ANSWER 9 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN **13623-11-5** REGISTRY
CN Thiazole, trimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thiazole, 2,4,5-trimethyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2,4,5-Trimethylthiazole
CN NSC 170614
CN Trimethylthiazole
FS 3D CONCORD
MF **C6 H9 N S**
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

149 REFERENCES IN FILE CA (1907 TO DATE)
149 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:6779

REFERENCE 2: 138:401896

REFERENCE 3: 138:390526

REFERENCE 4: 137:93744

REFERENCE 5: 137:78191

REFERENCE 6: 137:14996

REFERENCE 7: 136:290698

REFERENCE 8: 136:246626

REFERENCE 9: 136:52910

REFERENCE 10: 135:150221

L60 ANSWER 10 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 774-50-5 REGISTRY
CN **2-Thiazolamine, 5-(4-fluorophenyl)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thiazole, 2-amino-5-(p-fluorophenyl)- (7CI, 8CI)
FS 3D CONCORD
MF **C9 H7 F N2 S**
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 101:54977

REFERENCE 2: 94:121514

REFERENCE 3: 92:128793

REFERENCE 4: 57:10831

L60 ANSWER 11 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN **457-59-0** REGISTRY
CN 2-Thiazolamine, N-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Thiazoline, 2-(p-fluoroanilino)- (8CI)
FS 3D CONCORD
MF C9 H9 F N2 S
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CHEMCATS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:209215

REFERENCE 2: 134:162957

REFERENCE 3: 128:189475

L60 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN **288-47-1** REGISTRY
CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C3 H3 N S**
CI COM, RPS
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2365 REFERENCES IN FILE CA (1907 TO DATE)
415 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2367 REFERENCES IN FILE CAPLUS (1907 TO DATE)
37 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 140:145601

REFERENCE 2: 140:136181

REFERENCE 3: 140:128286

REFERENCE 4: 140:111367

REFERENCE 5: 140:104451

REFERENCE 6: 140:97781

REFERENCE 7: 140:94092

REFERENCE 8: 140:93825

REFERENCE 9: 140:79851

REFERENCE 10: 140:42043

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:48:32 ON 10 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Mar 2004 VOL 140 ISS 11
FILE LAST UPDATED: 9 Mar 2004 (20040309/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot l83

L83 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:521496 HCAPLUS
DN 137:93744
ED Entered STN: 12 Jul 2002
TI Preparation of thiazole derivatives for the treatment of fibrotic diseases
IN **Wagle, Dilip**; Martin, Gail; Bell, Stanely C.; Lavoie, Edmond J.
PA **Alteon, Inc., USA**
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-541
ICS A61K031-5377; A61K031-496; A61K031-454; A61K031-421; A61K031-426
CC 28-7 (**Heterocyclic** Compounds (More Than One **Hetero** Atom))
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053161	A1	20020711	WO 2001-US50822	20011228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1353676	A1	20031022	EP 2001-991611	20011228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002183317	A1	20021205	US 2001-38116	20011231
	US 6596744	B2	20030722		
	US 2003225146	A1	20031204	US 2003-440896	20030519
PRAI	US 2000-259107P	P	20001229		
	US 2001-259239P	P	20010102		
	US 2001-296247P	P	20010606		
	WO 2001-US50822	W	20011228		
	US 2001-38116	A1	20011231		

OS MARPAT 137:93744

GI



I



II

AB Provided is a method of decreasing intraocular pressure or improving ocular accommodation, comprising administration of I, II [J = O, S, NR'; Ra-b = H, acylamino, acyloxyalkyl, alkanoyl, alkenyl, alkoxy, etc.; R' = alkyl, alkenyl, H, Ar; Rc = oxo, H, alkyl, alkylthio, H, mercapto, amino, amino-alkyl, etc.]. For instance, 3,5-dimethylphenol was alkylated with bromoacetic acid (110°, 4 h) to yield (3,5-dimethylphenoxy)acetic acid which was coupled to 2-aminothiazole (CH2Cl2, EDCI, HOBt, NMM) to give 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide. The activity of example compds. in breaking, reversing or inhibiting the formation of advanced glycosylation end products (AGEs) or AGE-mediated cross-links was determined (no data).

ST fibrotic disease thiazole prepn

IT Fibrosis
Human
(preparation of thiazole derivs. for treatment of fibrotic diseases)

IT **288-47-1P**, Thiazole **13623-11-5P**, 2,4,5-Trimethylthiazole **18640-74-9P**, 2-Isobutylthiazole **19952-47-7P**, 2-Amino-4-chlorobenzothiazole **109317-64-8P** 181070-25-7P, 2,6-Diaminobenzothiazole dihydrochloride **289491-05-0P** **302559-76-8P**, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide **441285-73-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of thiazole derivs. for treatment of fibrotic diseases)

IT 73326-20-2P, 2-(2-Bromoacetamido)thiazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thiazole derivs. for treatment of fibrotic diseases)

IT 79-08-3, Bromoacetic acid 88-14-2, 2-Furoic acid 92-36-4, 2-(4-Aminophenyl)-6-methylbenzothiazole 96-50-4, 2-Aminothiazole 108-68-9, 3,5-Dimethylphenol 527-69-5, 2-Furoyl chloride 598-21-0, Bromoacetyl bromide 6285-57-0, 2-Amino-6-nitrobenzothiazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of thiazole derivs. for treatment of fibrotic diseases)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cerami; US 6007865 A 1999 HCAPLUS
(2) Wagle; US 6121300 A 2000 HCAPLUS

IT **288-47-1P**, Thiazole **13623-11-5P**, 2,4,5-Trimethylthiazole **18640-74-9P**, 2-Isobutylthiazole **19952-47-7P**, 2-Amino-4-chlorobenzothiazole **109317-64-8P** **289491-05-0P** **302559-76-8P**, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide **441285-73-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of thiazole derivs. for treatment of fibrotic diseases)

RN 288-47-1 HCAPLUS

CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)

RN 13623-11-5 HCAPLUS
CN Thiazole, trimethyl- (9CI) (CA INDEX NAME)



RN 18640-74-9 HCAPLUS
CN Thiazole, 2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 19952-47-7 HCAPLUS
CN 2-Benzothiazolamine, 4-chloro- (9CI) (CA INDEX NAME)



RN 109317-64-8 HCAPLUS
CN 7(4H)-Benzothiazolone, 5,6-dihydro-5,5-dimethyl-2-(2-naphthalenylamino)-(9CI) (CA INDEX NAME)



RN 289491-05-0 HCAPLUS
CN 2-Furancarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (9CI) (CA INDEX NAME)



RN 302559-76-8 HCAPLUS
CN Acetamide, 2-(3,5-dimethylphenoxy)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 441285-73-0 HCAPLUS
CN 2-Thiazolidinamine, N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



L83 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:521487 HCAPLUS
DN 137:93743
ED Entered STN: 12 Jul 2002
TI Preparation of thiazole derivatives as antiglaucoma agents
IN **Wagle, Dilip**; Gall, Martin; Bell, Stanley C.; Lavoie, Edmond J.
PA **Alteon, Inc., USA**
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-425
CC 28-7 (**Heterocyclic** Compounds (More Than One **Hetero** Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002053156	A1	20020711	WO 2001-US49834	20011228

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1359910 A1 20031112 EP 2001-988373 20011228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2002119970 A1 20020829 US 2001-36856 20011231
PRAI US 2000-259428P P 20001229
US 2001-296258P P 20010606
WO 2001-US49834 W 20011228
OS MARPAT 137:93743
GI



I



II

AB Provided is a method of decreasing intraocular pressure or improving ocular accommodation, comprising administration of I, II [J = O, S, NR'; Ra-b = H, acylamino, acyloxyalkyl, alkanoyl, alkenyl, alkoxy, etc.; R' = alkyl, alkenyl, H, Ar; Rc = oxo, H, alkyl, alkylthio, H, mercapto, amino, amino-alkyl, etc.]. For instance, 3,5-dimethylphenol was alkylated with bromoacetic acid (110°, 4 h) to yield (3,5-dimethylphenoxy)acetic acid which was coupled to 2-aminothiazole (CH2Cl2, EDCI, HOBt, NMM) to give 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide. The activity of example compds. in breaking, reversing or inhibiting the formation of advanced glycosylation end products (AGEs) or AGE-mediated cross-links was determined (no data).

ST glaucoma intraocular pressure accommodation thiazole prepn

IT Antiglaucoma agents
Glaucoma (disease)
Human
(preparation of thiazole derivs. as antiglaucoma agents)

IT **302559-76-8P**, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiglaucoma agent; preparation of thiazole derivs. as antiglaucoma agents)

IT 181070-25-7P, 2,6-Diaminobenzothiazole dihydrochloride
289491-05-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiglaucoma agents; preparation of thiazole derivs. as antiglaucoma agents)

IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; preparation of thiazole derivs. as antiglaucoma agents)

IT 73326-20-2P, 2-(2-Bromoacetamido)thiazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thiazole derivs. as antiglaucoma agents)

IT 79-08-3, Bromoacetic acid 88-14-2, 2-Furoic acid 92-36-4, 2-(4-Aminophenyl)-6-methylbenzothiazole 96-50-4, 2-Aminothiazole 108-68-9, 3,5-Dimethylphenol 527-69-5, 2-Furoyl chloride 598-21-0, Bromoacetyl bromide 6285-57-0, 2-Amino-6-nitrobenzothiazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of thiazole derivs. as antiglaucoma agents)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Thomspon; US 5718912 A 1998 HCAPLUS

IT **302559-76-8P**, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiglaucoma agent; preparation of thiazole derivs. as antiglaucoma agents)

RN 302559-76-8 HCAPLUS

CN Acetamide, 2-(3,5-dimethylphenoxy)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



IT **289491-05-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiglaucoma agents; preparation of thiazole derivs. as antiglaucoma agents)

RN 289491-05-0 HCAPLUS

CN 2-Furancarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (9CI) (CA INDEX NAME)



L83 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN **2001:545486** HCAPLUS

DN **135:122497**

ED Entered STN: 27 Jul 2001

TI Preparation of thiazole, imidazole, and oxazole compounds for treatment of disorders associated with protein **aging**.

IN **Wagle, Dilip; Vasan, Sara; Egan, John J.**

PA **Alteon, Inc., USA**

SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

DT Patent

LA English

IC A61K031-42; A61K031-415; A61K031-425

CC 28-7 (**Heterocyclic** Compounds (More Than One **Hetero** Atom))
Section cross-reference(s): **1**

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001052847	A1	20010726	WO 2001-US1799	20010119
	WO 2001052847	C1	20020926		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU	2001032864	A5	20010731	AU 2001-32864	20010119
US	2002022622	A1	20020221	US 2001-766547	20010119 <--
EP	1248615	A1	20021016	EP 2001-904934	20010119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP	2004501863	T2	20040122	JP 2001-552895	20010119
US	2003225146	A1	20031204	US 2003-440896	20030519
PRAI US	2000-176995P	P	20000119		
US	2000-183274P	P	20000217		
US	2000-259107P	P	20001229		
US	2000-259291P	P	20001229		
US	2001-259237P	P	20010102		
US	2001-259239P	P	20010102		
WO	2001-US1799	W	20010119		
US	2001-296247P	P	20010606		
US	2001-38116	A1	20011231		

OS MARPAT 135:122497

GI



I

AB A method of treating diabetes, kidney damage, blood vessel damage, atherosclerosis, peripheral vascular disease, coronary heart disease, heart failure, hypertension, retinopathy, peripheral neuropathy, cataracts, arthritis, Alzheimer's disease, tissue damage caused by contact with reducing sugars, stroke, skin elasticity reduction, and of increasing red blood cell deformability comprises administration of title compds. [I; J = O, S, NR4; R1, R2 = H, acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, allyl, amino, etc.; R1R2 = atoms to form a fused (substituted) aryl, cycloalkyl, heterocyclyl, or heteroaryl ring; R3 = O, H, alkyl, alkylthio, H, SH, amino, aminoalkyl, aminoaryl, etc.; R4 = alkyl, alkenyl, H, aryl; n = 0, 1] (no data). Thus, 2-amino-6-nitrobenzothiazole was hydrogenated in MeOH over Pd/C at 60 psi for 6.5 h at room temperature to give 2,6-diaminobenzothiazole dihydrochloride.

ST thiazole imidazole oxazole prepn protein **aging** inhibitor; diabetes treatment thiazole imidazole oxazole prep; kidney damage treatment thiazole imidazole oxazole prep; blood vessel damage treatment thiazole imidazole oxazole prep; atherosclerosis treatment thiazole imidazole oxazole prep; retinopathy treatment thiazole imidazole oxazole prep; arthritis treatment thiazole imidazole oxazole prep

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)

IT Artery, disease
(coronary, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)

IT Erythrocyte
(deformability improvement; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Heart, disease
(failure, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Kidney, disease
(injury, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Nerve, disease
(peripheral neuropathy, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Blood vessel, disease
(peripheral, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Anti-Alzheimer's agents
Antiarthritics
Antidiabetic agents
Antihypertensives
(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Carbohydrates, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(reducing sugars, treatment of tissue damage due to contact with reducing sugars; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Eye, disease
(retinopathy, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Brain, disease
(stroke, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Proteins, general, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(treatment of **aging**; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Blood vessel
(treatment of blood vessel damage; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Diabetes mellitus
(treatment of complications; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT **Aging, animal**
(treatment of protein **aging**; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Skin
(treatment of skin elasticity reduction; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
IT Animal tissue
(treatment of tissue damage due to contact with reducing sugars; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders

associated with protein **aging**)

IT Cataract
(treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)

IT 5407-51-2P, 2,6-Diaminobenzothiazole 181070-25-7P **289491-05-0P** **302559-76-8P**
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)

IT 88-14-2, 2-Furoic acid 92-36-4, 2-(4-Aminophenyl)-6-methylbenzothiazole 96-50-4, 2-Aminothiazole 108-68-9, 3,5-Dimethylphenol 527-69-5, 2-Furoyl chloride 598-21-0, Bromoacetyl bromide 6285-57-0, 2-Amino-6-nitrobenzothiazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)

IT 88-14-2, 2-Furoic acid 92-36-4, 2-(4-Aminophenyl)-6-methylbenzothiazole 96-50-4, 2-Aminothiazole 108-68-9, 3,5-Dimethylphenol 527-69-5, 2-Furoyl chloride 598-21-0, Bromoacetyl bromide 6285-57-0, 2-Amino-6-nitrobenzothiazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cerami; US 5853703 A 1998 HCAPLUS
(2) Chatterjee; WO 9941220 A1 1999 HCAPLUS
(3) Lai, C; WO 9966924 A1 1999 HCAPLUS

IT **289491-05-0P** **302559-76-8P**
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)

RN 289491-05-0 HCAPLUS

CN 2-Furancarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (9CI) (CA INDEX NAME)



RN 302559-76-8 HCAPLUS

CN Acetamide, 2-(3,5-dimethylphenoxy)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



L83 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
AN **2000:98234** HCAPLUS
DN **132:146649**
ED Entered STN: 11 Feb 2000
TI Sulfonamide derivatives for potentiating glutamate receptor function, preparation thereof, pharmaceutical compositions, and therapeutic use
IN Arnold, Macklin Brian; Bleisch, Thomas John; Ornstein, Paul Leslie; Smith, Edward C.; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-11 (**Pharmacology**)
Section cross-reference(s): 25, 27, **63**

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006083	A2	20000210	WO 1999-US17018	19990728
	WO 2000006083	A3	20000713		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2338994	AA	20000210	CA 1999-2338994	19990728
	AU 9952356	A1	20000221	AU 1999-52356	19990728
	US 6500865	B1	20021231	US 2001-744413	20010123
PRAI	US 1998-94970P	P	19980731		
	WO 1999-US17018	W	19990728		

OS MARPAT 132:146649
AB The invention provides sulfonamide derivs. useful for potentiating glutamate receptor function in a mammal and therefore useful for treating a wide variety of conditions, e.g. psychiatric and neurol. disorders. Preparation of e.g. N-[4-(3-thienyl)-1-phenylethyl]-2-propanesulfonamide is described.
ST sulfonamide deriv prepn glutamate receptor therapeutic; propanesulfonamide deriv prepn glutamate receptor therapeutic; psychiatric neurol disorder sulfonamide deriv prepn
IT **Aging, animal**
(age-related dementia and memory impairment; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT Mental disorder
(attention deficit disorder; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)

IT Mental disorder
(attention deficit hyperactivity disorder; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT Drug delivery systems
(capsules; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT Nervous system
(degeneration; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT Mental disorder
(dementia, age-related; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT Drugs
(drug-induced psychosis; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT Mental disorder
(psychosis, cognitive deficit associated with; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT Antidepressants
Antipsychotics
Cognition enhancers
Drug delivery systems
Movement disorders
Nervous system agents
(sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT Drug delivery systems
(tablets; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT 14062-25-0P, Ethyl 4-bromophenylacetate 73918-56-6P, 2-(4-Bromophenyl)ethylamine 131818-17-2P 133778-10-6P 211315-18-3P 211315-19-4P 211315-20-7P 256381-10-9P 257604-10-7P 257604-11-8P 257604-12-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT 106-40-1, 4-Bromoaniline 124-63-0, Methanesulfonyl chloride **288-47-1**, Thiazole 298-12-4, Glyoxylic acid 623-00-7, 4-Bromobenzonitrile 813-19-4, Bis(tributyltin) 1072-85-1, 2-Fluorobromobenzene 1562-34-1 1878-68-8, 4-Bromophenylacetic acid 5391-88-8 5419-55-6, Triisopropyl borate 6165-69-1, Thiophene-3-boronic acid 10147-37-2, Isopropylsulfonyl chloride 22627-70-9, 3-Ethoxy-2-cyclopenten-1-one 24424-99-5, Di-tert-butyl dicarbonate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT 257604-08-3P 257604-09-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT 1765-93-1P, 4-Fluorobenzeneboronic acid 74213-24-4P, Dibromoformaldoxime 86108-58-9P, 2-Trimethylstannylthiazole 112080-39-4P 120157-97-3P

126747-14-6P, 4-Cyanophenylboronic acid 133778-14-0P 185399-96-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
IT **288-47-1**, Thiazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
RN 288-47-1 HCAPLUS
CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)

L83 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
AN **1999:25966** HCAPLUS
DN **130:100661**
ED Entered STN: 13 Jan 1999
TI Thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
IN Cerami, Anthony; Ulrich, Peter C.; **Wagle, Dilip R.**; Hwang, San-Bao; **Vasan, Sara**; **Egan, John J.**
PA The Picower Institute for Medical Research, USA; **Alteon Inc.**
SO U.S., 30 pp., Cont.-in-part of U.S. Ser. No. 473,104, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-38
ICS C07D277-24
NCL 424053000
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): **1**, 17, **28**, 62
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5853703	A	19981229	US 1996-588249	19960118
	US 5656261	A	19970812	US 1995-375155	19950118
	CA 2210684	AA	19960725	CA 1996-2210684	19960118
	WO 9622095	A2	19960725	WO 1996-US663	19960118
	WO 9622095	A3	19970227		
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9647599	A1	19960807	AU 1996-47599	19960118
	AU 714607	B2	20000106		
	EP 808163	A2	19971126	EP 1996-903540	19960118
	EP 808163	B1	20030723		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	CN 1185736	A	19980624	CN 1996-192393	19960118
	JP 10512864	T2	19981208	JP 1996-522379	19960118
	BR 9607598	A	19991130	BR 1996-7598	19960118
	EP 1327887	A2	20030716	EP 2003-75955	19960118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 245420	E	20030815	AT 1996-903540	19960118
	PT 808163	T	20031231	PT 1996-96903540	19960118
	FI 9703031	A	19970915	FI 1997-3031	19970717

	NO 9703308	A	19970918	NO 1997-3308	19970717
	US 6007865	A	19991228	US 1997-971878	19971119
	US 38330	E	20031125	US 1999-373345	19990812
	US 6440749	B1	20020827	US 1999-470482	19991222
	US 2002192842	A1	20021219	US 2002-174883	20020619
	US 2004034074	A1	20040219	US 2003-418398	20030418
PRAI	US 1995-375155	A2	19950118		
	US 1995-473104	B2	19950607		
	US 1995-473184	A	19950607		
	EP 1996-903540	A3	19960118		
	US 1996-588249	A	19960118		
	WO 1996-US663	W	19960118		
	US 1997-971878	A3	19971119		
	US 1999-470482	A3	19991222		
	US 2002-174883	A1	20020619		

OS MARPAT 130:100661

AB The present invention relates to compns. and methods for inhibiting and reversing nonenzymic crosslinking (protein **aging**). Accordingly, compns. are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which addnl. reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain agents useful are thiazolium salts. The method comprises contacting the target protein with the composition Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein **aging** can be treated. A novel immunoassay for detection of the reversal of the nonenzymic crosslinking is also disclosed.

ST thiazolium deriv advanced glycosylation endproduct inhibitor; dentifrice thiazolium deriv advanced glycosylation endproduct inhibitor; food preservative thiazolium deriv advanced glycosylation endproduct inhibitor; **aging** inhibitor thiazolium deriv advanced glycosylation endproduct inhibitor

IT Glycoproteins, specific or class
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(AGE (advanced glycosylation end product); thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Immunoglobulins
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(G, erythrocyte-linked, decrease of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Erythrocyte
(IgG crosslinked to, decrease of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Proteins, general, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**aging** of, prevention of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Tooth
(discoloration of, prevention of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Diabetes mellitus
(glucose crosslinking in; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Collagens, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process);

BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(glucose crosslinking of, decrease of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Crosslinking
(reversal of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Albumins, processes
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(serum, crosslinking of, reversal of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Drug delivery systems
(tablets; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT **Aging, animal**
Dentifrices
Food preservation
Glycosylation
Maillard reaction
(thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 4568-71-2P 5304-34-7P 6274-00-6P 7467-00-7P 7478-09-3P
16311-69-6P 52197-73-6P 53995-67-8P 54016-70-5P 57132-40-8P
57168-49-7P 57168-62-4P 61544-06-7P 74360-51-3P 74385-09-4P
87910-71-2P 97380-14-8P 121704-45-8P 132416-79-6P 138404-41-8P
159356-41-9P 181069-78-3P 181069-79-4P 181069-80-7P 181069-81-8P
181069-82-9P 181069-83-0P 181069-84-1P 181069-85-2P 181069-86-3P
181069-89-6P 181069-90-9P 181069-91-0P 181069-92-1P 181069-93-2P
181069-95-4P 181069-96-5P 181069-98-7P 181069-99-8P 181070-00-8P
181070-03-1P 181070-04-2P 181070-05-3P 181070-06-4P 181070-07-5P
181070-08-6P 181070-09-7P 181070-10-0P 181070-11-1P 181070-12-2P
181070-13-3P 181070-14-4P 181070-16-6P 181070-22-4P 181070-25-7P
181070-26-8P 181070-27-9P 181070-28-0P 181070-29-1P 181070-30-4P
181070-31-5P 181070-35-9P 181070-36-0P 181070-37-1P 181070-39-3P
181070-40-6P 181070-43-9P 181070-44-0P 181070-46-2P 181070-48-4P
181070-49-5P 181070-50-8P 181070-51-9P 181070-52-0P 181070-53-1P
181070-54-2P 181070-55-3P 181070-56-4P 181070-57-5P 181070-59-7P
181070-61-1P 181070-62-2P 181070-63-3P 181070-64-4P 181070-65-5P
181070-66-6P 181070-67-7P 181070-68-8P 181070-69-9P 181070-70-2P
181070-71-3P 219305-49-4P 219305-51-8P 219305-56-3P 219305-64-3P
219305-70-1P 219305-74-5P 219305-81-4P 219305-83-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 181070-72-4P 181070-74-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 96-32-2, Methyl bromoacetate **288-47-1**, Thiazole 579-07-7,
1-Phenyl-1,2-propanedione 3581-91-7, 4,5-Dimethyl thiazole 36016-40-7,
o-Mesitylenesulfonylhydroxylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; DE 2323465 1973 HCAPLUS

(2) Anon; EP 167139 1986 HCAPLUS
(3) Anon; EP 170037 1986
(4) Anon; JP 1143855 1989
(5) Anon; EP 364344 1990 HCAPLUS
(6) Anon; JP 60184038 1990 HCAPLUS
(7) Anon; EP 586806 1994 HCAPLUS
(8) Anon; EP 614886 1994 HCAPLUS
(9) Anon; WO 9411490 1994 HCAPLUS
(10) Anon; WO 9420083 1994 HCAPLUS
(11) Archer; J Med Chem 1979, V22, P306 HCAPLUS
(12) Barranco; US 5366885 1994 HCAPLUS
(13) Brownlee; Diabetes Abstract 166 1986, V42A(Suppl)
(14) Brownlee; Science 1986, V232, P1629 HCAPLUS
(15) Bucala; Advances in Pharmacology 1992, V23, P1 HCAPLUS
(16) Cerami; US 4758583 1988
(17) Chang; J Biol Chem 1985, V260, P7970 HCAPLUS
(18) Dominianni; US 4609670 1986 HCAPLUS
(19) Dominianni; US 4683312 1987 HCAPLUS
(20) Dominianni; J Med chem 1989, V32, P2301 HCAPLUS
(21) Eble; J Biol Chem 1983, V258, P9406 HCAPLUS
(22) Gandasegui; Heterocycles 1990, V31, P1801 HCAPLUS
(23) Hayase; J Biol Chem 1989, V263, P3758
(24) Kawakishi; Maillard React Chem Food Health 1994, V151, P281 HCAPLUS
(25) Makita; J Biol Chem 1992, V267, P5133 HCAPLUS
(26) Neurath; US 5230998 1993 HCAPLUS
(27) Nicholls; Lab Invest 1989, V60, P486 HCAPLUS
(28) Nordbo; J Dent Res 1979, V58, P1429
(29) Oimomi; Agric Biol Chem 1989, V53, P1727 HCAPLUS
(30) Pongor; Proc Natl Acad Sci USA 1984, V81, P2684 HCAPLUS
(31) Potts; J Org Chem V41, P187 HCAPLUS
(32) Potts; J Org Chem 1977, V42, P1648 HCAPLUS
(33) Sell; J Biol Chem 1989, V264, P21597 HCAPLUS
(34) Singh; Tetrahedron 1992, V48, P4545 HCAPLUS
(35) Tamura; Synthesis 1977, V1, P1
(36) Tsuge; Chem Lett 1982, V5, P711
(37) Ulrich; US 5108930 1992 HCAPLUS
(38) Ulrich; US 5262152 1993 HCAPLUS
(39) Ulrich; Modern Aging Res 1985, V7, P83 HCAPLUS
(40) Voller; Enzyme Immunoassays Alternative Immunoassays 1985, P77

IT **288-47-1**, Thiazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

RN 288-47-1 HCAPLUS
CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)

L83 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:560531 HCAPLUS
DN 125:204548
ED Entered STN: 20 Sep 1996
TI Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
IN Cerami, Anthony; Ulrich, Peter C.; **Wagle, Dilip R.**; Hwang, San-bao; **Vasan, Sara**; **Egan, John J.**
PA **Alteon Inc., USA**; The Picower Institute for Medical Research
SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-425
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): 17, **28**, 62
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9622095	A2	19960725	WO 1996-US663	19960118
	WO 9622095	A3	19970227		
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5656261	A	19970812	US 1995-375155	19950118
	AU 9647599	A1	19960807	AU 1996-47599	19960118
	AU 714607	B2	20000106		
	EP 808163	A2	19971126	EP 1996-903540	19960118
	EP 808163	B1	20030723		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	JP 10512864	T2	19981208	JP 1996-522379	19960118
	US 5853703	A	19981229	US 1996-588249	19960118
	BR 9607598	A	19991130	BR 1996-7598	19960118
	AT 245420	E	20030815	AT 1996-903540	19960118
	FI 9703031	A	19970915	FI 1997-3031	19970717
	NO 9703308	A	19970918	NO 1997-3308	19970717
	US 38330	E	20031125	US 1999-373345	19990812
PRAI	US 1995-375155	A	19950118		
	US 1996-588249	A	19960118		
	US 1995-473104	B2	19950607		
	US 1995-473184	A	19950607		
	WO 1996-US663	W	19960118		

OS MARPAT 125:204548
AB Compns. and methods for inhibiting and reversing nonenzymic crosslinking (protein **aging**) are disclosed. Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins (such as thiazolium salts), and which addnl. reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving α-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein **aging** can be treated. A novel immunoassay for detection of the reversal of the nonenzymic crosslinking is also disclosed. Thiazole 850 mg, Me bromoacetate 1.52 mg, and absolute ethanol 50 mL were refluxed for 2 h, then cooled and the salt separated and recrystd. to obtain 3-(2-methoxy-2-oxoethyl)-thiazolium bromide (I). A lotion contained I 1.0, ethanol 200.0, PEG-400 300.0, hydroxypropyl cellulose 5.0 mg, and propylene glycol q.s. 1.0 g.
ST thiazolium deriv advanced glycosylation endproduct prevention; lotion thiazolium bromide deriv protein **aging**
IT Proteins, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**aging**; use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)
IT Dentifrices
Mouthwashes
(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)
IT Antibodies
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Glycoproteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AGE (advanced glycosylation end product), use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Pharmaceutical dosage forms
(lotions, use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Pharmaceutical dosage forms
(tablets, use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 4568-71-2P 5304-34-7P 6274-00-6P 7467-00-7P 7478-09-3P
16311-69-6P 52197-73-6P 53995-67-8P 54016-70-5P 57132-40-8P
57168-49-7P 57168-62-4P 61544-06-7P 74360-51-3P 74385-09-4P
87910-71-2P 97380-14-8P 121704-45-8P 132416-79-6P 138404-41-8P
159356-41-9P 181069-78-3P 181069-79-4P 181069-80-7P 181069-81-8P
181069-82-9P 181069-83-0P 181069-84-1P 181069-85-2P 181069-86-3P
181069-89-6P 181069-90-9P 181069-91-0P 181069-92-1P 181069-93-2P
181069-95-4P 181069-96-5P 181069-98-7P 181069-99-8P 181070-00-8P
181070-03-1P 181070-04-2P 181070-05-3P 181070-06-4P 181070-07-5P
181070-08-6P 181070-09-7P 181070-10-0P 181070-11-1P 181070-12-2P
181070-13-3P 181070-14-4P 181070-15-5P 181070-16-6P 181070-18-8P
181070-22-4P 181070-24-6P 181070-25-7P 181070-26-8P 181070-27-9P
181070-28-0P 181070-29-1P 181070-30-4P 181070-31-5P 181070-33-7P
181070-35-9P 181070-36-0P 181070-37-1P 181070-38-2P 181070-39-3P
181070-40-6P 181070-41-7P 181070-43-9P 181070-44-0P 181070-46-2P
181070-48-4P 181070-49-5P 181070-50-8P 181070-51-9P 181070-52-0P
181070-53-1P 181070-54-2P 181070-55-3P 181070-56-4P 181070-57-5P
181070-58-6P 181070-59-7P 181070-60-0P 181070-61-1P 181070-62-2P
181070-63-3P 181070-64-4P 181070-65-5P 181070-66-6P 181070-67-7P
181070-68-8P 181070-69-9P 181070-70-2P 181070-71-3P 181070-72-4P
181070-74-6P 181147-74-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 96-32-2, Methyl bromoacetate **288-47-1**, Thiazole 3581-91-7, 4,5-Dimethylthiazole 58042-39-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT **288-47-1**, Thiazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

RN 288-47-1 HCAPLUS
CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)

=>